Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Laryngostenosis | 6 | 2023 | 38 | 0.900 |
Why?
|
| Hypopharynx | 2 | 2016 | 10 | 0.560 |
Why?
|
| Vocal Cord Paralysis | 4 | 2022 | 68 | 0.530 |
Why?
|
| Polyps | 2 | 2016 | 44 | 0.530 |
Why?
|
| Laryngeal Neoplasms | 5 | 2019 | 104 | 0.530 |
Why?
|
| Pharyngeal Diseases | 1 | 2016 | 20 | 0.520 |
Why?
|
| Esophageal Diseases | 1 | 2016 | 37 | 0.510 |
Why?
|
| Papilloma | 8 | 2003 | 23 | 0.460 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2019 | 874 | 0.430 |
Why?
|
| Vocal Cords | 5 | 2022 | 67 | 0.410 |
Why?
|
| Laryngoscopy | 5 | 2021 | 157 | 0.340 |
Why?
|
| Voice Disorders | 3 | 2003 | 19 | 0.320 |
Why?
|
| Laryngoplasty | 2 | 2022 | 27 | 0.310 |
Why?
|
| Zenker Diverticulum | 1 | 2008 | 4 | 0.300 |
Why?
|
| Airway Obstruction | 4 | 2016 | 168 | 0.280 |
Why?
|
| Esophagoscopy | 1 | 2008 | 165 | 0.270 |
Why?
|
| Tracheal Diseases | 2 | 2015 | 15 | 0.270 |
Why?
|
| Respiratory Tract Neoplasms | 5 | 1994 | 14 | 0.220 |
Why?
|
| Bronchial Neoplasms | 2 | 2003 | 15 | 0.220 |
Why?
|
| Tracheal Neoplasms | 2 | 2003 | 21 | 0.220 |
Why?
|
| Papillomaviridae | 2 | 2003 | 189 | 0.200 |
Why?
|
| Pharyngeal Neoplasms | 3 | 1999 | 33 | 0.200 |
Why?
|
| Parkinsonian Disorders | 1 | 2003 | 77 | 0.200 |
Why?
|
| Aorta, Thoracic | 2 | 2018 | 536 | 0.200 |
Why?
|
| Head and Neck Neoplasms | 6 | 2002 | 699 | 0.190 |
Why?
|
| Collagen | 1 | 2003 | 334 | 0.190 |
Why?
|
| Botulinum Toxins | 2 | 1996 | 125 | 0.190 |
Why?
|
| Voice Quality | 2 | 2016 | 21 | 0.180 |
Why?
|
| Middle Aged | 27 | 2022 | 29432 | 0.180 |
Why?
|
| Tracheotomy | 1 | 2001 | 36 | 0.170 |
Why?
|
| Cricoid Cartilage | 1 | 2020 | 16 | 0.160 |
Why?
|
| Recurrent Laryngeal Nerve Injuries | 2 | 2018 | 15 | 0.160 |
Why?
|
| Treatment Outcome | 14 | 2023 | 13014 | 0.160 |
Why?
|
| Radiodermatitis | 1 | 2019 | 8 | 0.160 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2003 | 644 | 0.160 |
Why?
|
| Administration, Topical | 1 | 2019 | 144 | 0.160 |
Why?
|
| Esomeprazole | 1 | 2019 | 33 | 0.160 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2003 | 792 | 0.150 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 150 | 0.150 |
Why?
|
| Postoperative Complications | 4 | 2018 | 3227 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2003 | 1316 | 0.150 |
Why?
|
| Larynx | 2 | 2018 | 78 | 0.150 |
Why?
|
| Male | 35 | 2022 | 65941 | 0.150 |
Why?
|
| Aged, 80 and over | 8 | 2016 | 7215 | 0.150 |
Why?
|
| Retrospective Studies | 14 | 2023 | 17497 | 0.140 |
Why?
|
| Mucociliary Clearance | 1 | 1997 | 5 | 0.140 |
Why?
|
| Endoscopy | 2 | 2016 | 291 | 0.140 |
Why?
|
| Ethmoid Sinus | 1 | 1997 | 9 | 0.140 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 1997 | 13 | 0.140 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 1997 | 18 | 0.140 |
Why?
|
| Fibrosis | 1 | 2019 | 464 | 0.140 |
Why?
|
| Aged | 17 | 2019 | 21754 | 0.140 |
Why?
|
| Neurilemmoma | 2 | 1997 | 48 | 0.140 |
Why?
|
| Humans | 48 | 2023 | 134000 | 0.130 |
Why?
|
| Female | 32 | 2022 | 71722 | 0.130 |
Why?
|
| Verbal Behavior | 1 | 1996 | 52 | 0.130 |
Why?
|
| Tracheostomy | 2 | 2015 | 201 | 0.130 |
Why?
|
| Gastroesophageal Reflux | 1 | 1999 | 336 | 0.120 |
Why?
|
| Adult | 25 | 2021 | 31983 | 0.120 |
Why?
|
| Multiple Endocrine Neoplasia | 3 | 1992 | 23 | 0.120 |
Why?
|
| Disease Management | 1 | 2019 | 561 | 0.120 |
Why?
|
| Osteochondrodysplasias | 1 | 2015 | 68 | 0.120 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 1386 | 0.120 |
Why?
|
| Isotretinoin | 2 | 1994 | 25 | 0.120 |
Why?
|
| Critical Care | 1 | 2001 | 693 | 0.120 |
Why?
|
| Recurrent Laryngeal Nerve | 1 | 2014 | 11 | 0.110 |
Why?
|
| Tourette Syndrome | 1 | 1996 | 158 | 0.110 |
Why?
|
| Tracheal Stenosis | 1 | 2014 | 33 | 0.110 |
Why?
|
| Recurrence | 3 | 2021 | 1471 | 0.110 |
Why?
|
| Amyloidosis | 3 | 1992 | 73 | 0.110 |
Why?
|
| Skin Diseases | 3 | 1992 | 135 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2014 | 2196 | 0.100 |
Why?
|
| Radiotherapy, Conformal | 3 | 2002 | 63 | 0.100 |
Why?
|
| Prospective Studies | 8 | 2023 | 6664 | 0.100 |
Why?
|
| Quality of Life | 3 | 2020 | 2144 | 0.100 |
Why?
|
| Inflammation | 1 | 2019 | 1599 | 0.090 |
Why?
|
| Spasm | 2 | 1990 | 52 | 0.090 |
Why?
|
| Reoperation | 2 | 2020 | 866 | 0.090 |
Why?
|
| Lymphatic Metastasis | 2 | 1990 | 453 | 0.090 |
Why?
|
| Facial Paralysis | 1 | 1990 | 34 | 0.090 |
Why?
|
| Cranial Nerve Diseases | 1 | 1990 | 27 | 0.080 |
Why?
|
| Parotid Neoplasms | 1 | 1990 | 17 | 0.080 |
Why?
|
| Constriction, Pathologic | 2 | 2023 | 241 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2019 | 3700 | 0.080 |
Why?
|
| Interferon Type I | 3 | 1991 | 115 | 0.080 |
Why?
|
| Esophageal Sphincter, Upper | 1 | 2008 | 5 | 0.080 |
Why?
|
| Dystonia | 1 | 1990 | 175 | 0.070 |
Why?
|
| Veterans | 1 | 2019 | 1761 | 0.070 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 5511 | 0.070 |
Why?
|
| Surveys and Questionnaires | 4 | 2020 | 3993 | 0.070 |
Why?
|
| Immunohistochemistry | 4 | 2003 | 1761 | 0.070 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 1985 | 8 | 0.060 |
Why?
|
| Cranial Nerves | 1 | 1985 | 19 | 0.060 |
Why?
|
| Facial Neoplasms | 1 | 1985 | 22 | 0.060 |
Why?
|
| Adolescent | 11 | 2018 | 20552 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2014 | 1981 | 0.060 |
Why?
|
| Radiation Injuries | 2 | 2002 | 165 | 0.050 |
Why?
|
| Injections, Intramuscular | 2 | 1996 | 198 | 0.050 |
Why?
|
| Time Factors | 3 | 2021 | 6591 | 0.050 |
Why?
|
| Xerostomia | 1 | 2002 | 12 | 0.050 |
Why?
|
| Vascular Surgical Procedures | 2 | 2018 | 559 | 0.050 |
Why?
|
| Skin | 2 | 2019 | 551 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 755 | 0.050 |
Why?
|
| Radiotherapy | 2 | 2019 | 148 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 1315 | 0.050 |
Why?
|
| Angiofibroma | 1 | 2000 | 5 | 0.040 |
Why?
|
| Paranasal Sinus Diseases | 2 | 1997 | 20 | 0.040 |
Why?
|
| Risk Factors | 2 | 2019 | 11104 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 506 | 0.040 |
Why?
|
| Heme Oxygenase-1 | 1 | 2019 | 32 | 0.040 |
Why?
|
| Glottis | 1 | 2019 | 31 | 0.040 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 1999 | 34 | 0.040 |
Why?
|
| Prognosis | 3 | 2019 | 5082 | 0.040 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 1999 | 15 | 0.040 |
Why?
|
| Sinusitis | 1 | 2000 | 118 | 0.040 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2019 | 132 | 0.040 |
Why?
|
| Salivary Gland Neoplasms | 1 | 1999 | 67 | 0.040 |
Why?
|
| Morbidity | 1 | 2019 | 255 | 0.040 |
Why?
|
| Models, Anatomic | 1 | 2019 | 104 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2019 | 131 | 0.040 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2018 | 27 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1999 | 470 | 0.040 |
Why?
|
| Melanoma | 1 | 1985 | 974 | 0.040 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1999 | 168 | 0.030 |
Why?
|
| Inpatients | 1 | 2022 | 537 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 290 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 2018 | 175 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 971 | 0.030 |
Why?
|
| Parotid Gland | 2 | 2002 | 21 | 0.030 |
Why?
|
| Cough | 1 | 1997 | 96 | 0.030 |
Why?
|
| Epithelium | 1 | 1997 | 370 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 319 | 0.030 |
Why?
|
| Voice | 1 | 2016 | 17 | 0.030 |
Why?
|
| Trachea | 1 | 1997 | 212 | 0.030 |
Why?
|
| Early Medical Intervention | 1 | 2016 | 31 | 0.030 |
Why?
|
| Child | 10 | 2003 | 25766 | 0.030 |
Why?
|
| Wound Healing | 1 | 2019 | 495 | 0.030 |
Why?
|
| Child, Preschool | 5 | 2003 | 14820 | 0.030 |
Why?
|
| Infant | 4 | 2003 | 13176 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 1997 | 332 | 0.030 |
Why?
|
| Neuroendocrine Tumors | 1 | 1995 | 55 | 0.030 |
Why?
|
| United States | 2 | 2021 | 11690 | 0.030 |
Why?
|
| Nose Neoplasms | 2 | 2000 | 34 | 0.030 |
Why?
|
| Maxillary Sinus | 1 | 1994 | 15 | 0.030 |
Why?
|
| Enophthalmos | 1 | 1994 | 15 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 2210 | 0.030 |
Why?
|
| Bone Resorption | 1 | 1994 | 53 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1994 | 72 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 746 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2016 | 473 | 0.030 |
Why?
|
| Carcinoma | 2 | 1993 | 322 | 0.030 |
Why?
|
| Thyroid Neoplasms | 2 | 1993 | 255 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1919 | 0.020 |
Why?
|
| Administration, Oral | 1 | 1994 | 730 | 0.020 |
Why?
|
| Radiography | 1 | 1994 | 826 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2019 | 1606 | 0.020 |
Why?
|
| Radiotherapy Dosage | 2 | 2002 | 231 | 0.020 |
Why?
|
| Young Adult | 2 | 2016 | 9902 | 0.020 |
Why?
|
| Facial Muscles | 1 | 1990 | 34 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3402 | 0.020 |
Why?
|
| Esophageal Neoplasms | 1 | 1994 | 393 | 0.020 |
Why?
|
| Electromyography | 1 | 1990 | 177 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 1997 | 1335 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 4825 | 0.020 |
Why?
|
| Pedigree | 2 | 1993 | 1696 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 3082 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 1994 | 1438 | 0.020 |
Why?
|
| Calcitonin | 1 | 1989 | 33 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 5186 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 4780 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1994 | 1353 | 0.020 |
Why?
|
| Texas | 1 | 2014 | 3689 | 0.020 |
Why?
|
| Melanocytes | 1 | 1985 | 50 | 0.020 |
Why?
|
| Schwann Cells | 1 | 1985 | 68 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1985 | 374 | 0.010 |
Why?
|
| Biopsy | 1 | 1989 | 1304 | 0.010 |
Why?
|
| Interferons | 1 | 1983 | 146 | 0.010 |
Why?
|
| Mice | 1 | 2019 | 18915 | 0.010 |
Why?
|
| Remission Induction | 1 | 1991 | 308 | 0.010 |
Why?
|
| Nasal Polyps | 1 | 2000 | 25 | 0.010 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2000 | 62 | 0.010 |
Why?
|
| Antibodies | 1 | 1991 | 382 | 0.010 |
Why?
|
| Immobilization | 1 | 1999 | 25 | 0.010 |
Why?
|
| Technology, Radiologic | 1 | 1999 | 12 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1999 | 74 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1999 | 237 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2000 | 668 | 0.010 |
Why?
|
| Animals | 1 | 2019 | 36401 | 0.010 |
Why?
|
| Random Allocation | 2 | 1988 | 450 | 0.010 |
Why?
|
| Hospitals, Voluntary | 1 | 1997 | 5 | 0.010 |
Why?
|
| Hospital Charges | 1 | 1997 | 63 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1999 | 814 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2000 | 1254 | 0.010 |
Why?
|
| Hospital Costs | 1 | 1997 | 187 | 0.010 |
Why?
|
| Ploidies | 1 | 1995 | 38 | 0.010 |
Why?
|
| Carcinoid Tumor | 1 | 1995 | 27 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1995 | 318 | 0.010 |
Why?
|
| Bone Remodeling | 1 | 1994 | 61 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 1988 | 1154 | 0.010 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 1993 | 7 | 0.010 |
Why?
|
| Orbit | 1 | 1994 | 107 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1995 | 836 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 1994 | 248 | 0.010 |
Why?
|
| Genes | 1 | 1993 | 450 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1993 | 631 | 0.010 |
Why?
|
| Syndrome | 1 | 1994 | 1165 | 0.010 |
Why?
|
| Meige Syndrome | 1 | 1990 | 9 | 0.010 |
Why?
|
| Pheochromocytoma | 1 | 1989 | 39 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1994 | 1486 | 0.010 |
Why?
|
| Hypothyroidism | 1 | 1990 | 100 | 0.000 |
Why?
|
| Tremor | 1 | 1990 | 135 | 0.000 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1989 | 80 | 0.000 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1988 | 397 | 0.000 |
Why?
|
| DNA | 1 | 1993 | 1674 | 0.000 |
Why?
|
| Biomarkers, Tumor | 1 | 1995 | 1720 | 0.000 |
Why?
|
| DNA, Viral | 1 | 1988 | 500 | 0.000 |
Why?
|
| Adenoma, Pleomorphic | 1 | 1985 | 6 | 0.000 |
Why?
|
| Neurofibroma | 1 | 1985 | 6 | 0.000 |
Why?
|
| Paraganglioma | 1 | 1985 | 25 | 0.000 |
Why?
|
| Laser Therapy | 1 | 1988 | 252 | 0.000 |
Why?
|
| Angiography | 1 | 1985 | 215 | 0.000 |
Why?
|
| Drug Compounding | 1 | 1983 | 43 | 0.000 |
Why?
|
| Lymphoma | 1 | 1985 | 335 | 0.000 |
Why?
|